Last reviewed · How we verify
PTG-300
At a glance
| Generic name | PTG-300 |
|---|---|
| Also known as | Rusfertide |
| Sponsor | Protagonist Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PTG-300 in Subjects With Hereditary Hemochromatosis (PHASE2)
- A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (PHASE3)
- Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) (PHASE2)
- Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera (PHASE3)
- PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (PHASE2)
- Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers (PHASE1)
- Safety Study for Beta Thalassemia Subjects on PTG-300 (PHASE2)
- Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTG-300 CI brief — competitive landscape report
- PTG-300 updates RSS · CI watch RSS
- Protagonist Therapeutics, Inc. portfolio CI